INS and type 2 diabetes mellitus: Our Memory Advancement with Intranasal Insulin in T2DM (MemAID) trial has shown that long-term (24-week, 40IU) INI treatment improved cognition, walking speed, decreased insulin resistance, and increased brain perfusion in the mPFC in T2DM adults and nondiabetic controls [26].